CA2385251A1 - Nouveaux composes imidazopyridine carbonitrile - Google Patents

Nouveaux composes imidazopyridine carbonitrile Download PDF

Info

Publication number
CA2385251A1
CA2385251A1 CA002385251A CA2385251A CA2385251A1 CA 2385251 A1 CA2385251 A1 CA 2385251A1 CA 002385251 A CA002385251 A CA 002385251A CA 2385251 A CA2385251 A CA 2385251A CA 2385251 A1 CA2385251 A1 CA 2385251A1
Authority
CA
Canada
Prior art keywords
alkyl
imidazopyridine
carbon atoms
compound according
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002385251A
Other languages
English (en)
Inventor
Margareta Herslof
Henrik Sorensen
Peter Nordberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2385251A1 publication Critical patent/CA2385251A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)

Abstract

L'invention concerne un inhibiteur sélectif de l'activité d'ostéoclastes de mammifères, leurs procédés de préparation et des compositions pharmaceutiques les contenant, ainsi que des méthodes de traitement consistant à administrer ledit inhibiteur sélectif à un patient humain ou animal. On a constaté que ledit inhibiteur sélectif inhibe la H?+¿-ATPase vacuolaire dans les ostéoclastes, et qu'il est donc efficace, au plan thérapeutique, contre les troubles physiologiques impliquant la résorption osseuse. Dans un mode de réalisation de l'invention, ledit inhibiteur comprend un composé imidazopyridine carbonitrile de formule générale I.
CA002385251A 1999-10-06 2000-09-26 Nouveaux composes imidazopyridine carbonitrile Abandoned CA2385251A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9903611A SE9903611D0 (sv) 1999-10-06 1999-10-06 Novel compounds III
SE9903611-3 1999-10-06
PCT/SE2000/001860 WO2001025237A1 (fr) 1999-10-06 2000-09-26 Nouveaux composes imidazopyridine carbonitrile

Publications (1)

Publication Number Publication Date
CA2385251A1 true CA2385251A1 (fr) 2001-04-12

Family

ID=20417271

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002385251A Abandoned CA2385251A1 (fr) 1999-10-06 2000-09-26 Nouveaux composes imidazopyridine carbonitrile

Country Status (6)

Country Link
EP (1) EP1222188A1 (fr)
JP (1) JP2003511381A (fr)
AU (1) AU7976400A (fr)
CA (1) CA2385251A1 (fr)
SE (1) SE9903611D0 (fr)
WO (1) WO2001025237A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016018555B1 (pt) 2014-02-13 2024-01-23 Incyte Holdings Corporation Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
WO2015123437A1 (fr) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
SG11201606689VA (en) 2014-02-13 2016-09-29 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
US10329255B2 (en) 2015-08-12 2019-06-25 Incyte Corporation Salts of an LSD1 inhibitor
WO2020047198A1 (fr) 2018-08-31 2020-03-05 Incyte Corporation Sels d'un inhibiteur de lsd1 et leurs procédés de préparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61218589A (ja) * 1985-03-26 1986-09-29 Eisai Co Ltd ５―（６―イミダゾ〔１，２―ａ〕ピリジニル）ピリジン誘導体
FR2581646B1 (fr) * 1985-05-07 1987-09-18 Synthelabo Derives d'imidazopyridine, leur preparation et leur application en therapeutique
DE69633196D1 (de) * 1995-10-16 2004-09-23 Fujisawa Pharmaceutical Co Heterocyclische verbindungen als h+-atpasen
DE69730837T2 (de) * 1996-07-09 2005-09-29 Nikem Research S.R.L., Baranzate Di Bollate Indolderivate zur behandlung von osteoporose

Also Published As

Publication number Publication date
SE9903611D0 (sv) 1999-10-06
EP1222188A1 (fr) 2002-07-17
WO2001025237A1 (fr) 2001-04-12
JP2003511381A (ja) 2003-03-25
AU7976400A (en) 2001-05-10

Similar Documents

Publication Publication Date Title
US10676468B2 (en) N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof
EP1549651B1 (fr) Pyrimidopyrimidones en tant qu'inhibiteurs de kinases
JP4205430B2 (ja) 疼痛を治療するための、バニロイド受容体アンタゴニストとして、使用するための縮合ピリジン誘導体
UA64741C2 (uk) Заміщені похідні імідазопіридину, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі (варіанти), спосіб пригнічення секреції шлункової кислоти або лікування шлунково-кишкових запалювальних захворювань та спосіб лікування або профілактики станів, пов'язаних з інфікуванням helicobacter pylori слизової оболонки шлунку
CN101410114A (zh) A3腺苷受体别构调节剂
KR20030085565A (ko) 티오하이단토인 유도체 및 당뇨병 치료를 위한 이들의 용도
JP5820080B2 (ja) 三環系ＰＩ３Ｋ及び／又はｍＴＯＲ抑制剤
AU2002247059B2 (en) Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK)
US6579884B1 (en) Compounds
AU2002247059A1 (en) Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK)
CA2385251A1 (fr) Nouveaux composes imidazopyridine carbonitrile
JP2013506004A (ja) ジヒドロオロット酸デヒドロゲナーゼの阻害剤である抗マラリア剤
JP2008526817A (ja) 新規のピロロジヒドロイソキノリン
NZ236038A (en) Tetrahydropyrimidin-2-one and imidazolidin-2-one derivatives in the treatment of asthma
EP1911760A1 (fr) Inhibiteur de xanthine oxydase
IE904622A1 (en) Imidazo[4,5-c]pyridines as antiosteoporotic agents
KR20040023742A (ko) 축합 다환식 화합물
AU7976300A (en) Novel trisubstituted pyridine compounds
EP1222170A1 (fr) Nouveaux composes nicotinonitriliques
JP2003520768A (ja) ＴＮＦα阻害剤として有用なチアゾロピリミジン
KR20150002952A (ko) 피리도피리미딘 유도체를 함유하는 대사성 골 질환의 예방 및 치료용 약학 조성물
CN109369675B (zh) 一种双-氟喹诺酮噁二唑脲类培氟沙星衍生物及其制备方法和应用
KAYA et al. THE EFFECTS OF A NOVEL DIHYDRO [3, 2-D] PYRIDINE SERIES ON HUMAN ERYTHROCYTE CARBONIC ANHYDRASE ENZYME I (HCAI) Tuna DEMİRCİ
UA81323C2 (en) Anthranylamide pyridones that inhibit vegfr-2 and vegfr-3
CN116354960A (zh) Shp2磷酸酶抑制剂

Legal Events

Date Code Title Description
FZDE Dead